{"id":11397,"date":"2023-09-15T09:47:59","date_gmt":"2023-09-15T09:47:59","guid":{"rendered":"https:\/\/prueba.ibima.eu\/?post_type=project&p=11397"},"modified":"2025-12-15T15:46:23","modified_gmt":"2025-12-15T15:46:23","slug":"da-06","status":"publish","type":"project","link":"https:\/\/ibima.eu\/en\/project\/da-06\/","title":{"rendered":"DA-06"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb background_image=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2023\/04\/FotoWeb-min-1000×500-1.jpg\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb250px||30px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|700|||||||\u00bb header_text_align=\u00bbcenter\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb40px\u00bb header_2_font=\u00bbPoppins|700|||||||\u00bb header_2_text_color=\u00bb#FFFFFF\u00bb header_2_font_size=\u00bb46px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Enfermedades Inflamatorias Inmunomediadas (IMID)<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb background_color=\u00bb#235b78″ custom_padding=\u00bb30px||30px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb header_3_font=\u00bbPoppins|700|||||||\u00bb header_3_text_color=\u00bb#FFFFFF\u00bb header_3_font_size=\u00bb34px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Lineas de Investigaci\u00f3n<\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb background_color=\u00bb#d3d6dd\u00bb custom_margin=\u00bb||||true|false\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb2″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb width=\u00bb70%\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#235b78″ text_font_size=\u00bb16px\u00bb text_line_height=\u00bb2.1em\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb2_3,1_3″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb2″ make_equal=\u00bbon\u00bb _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb width=\u00bb90%\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_tabs active_tab_background_color=\u00bb#105e7c\u00bb inactive_tab_background_color=\u00bb#41a7d4″ active_tab_text_color=\u00bb#FFFFFF\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb tab_text_color=\u00bb#FFFFFF\u00bb border_color_all=\u00bb#41a7d4″ global_colors_info=\u00bb{}\u00bb][et_pb_tab title=\u00bbProyectos\u00bb _builder_version=\u00bb4.24.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n[et_pb_section global_module=\"26404\"][\/et_pb_section]\n

\n
<\/div>\n<\/div>\n

[\/et_pb_tab][et_pb_tab title=\u00bbEstudios cl\u00ednicos\u00bb _builder_version=\u00bb4.24.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n[et_pb_section global_module=\"11331\"][\/et_pb_section]\n

\n
<\/div>\n<\/div>\n

[\/et_pb_tab][et_pb_tab title=\u00bbPublicaciones cient\u00edficas\u00bb _builder_version=\u00bb4.24.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n[et_pb_section global_module=\"11334\"][\/et_pb_section]\n

[\/et_pb_tab][et_pb_tab title=\u00bbOfertas tecnol\u00f3gicas\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"38432\"][\/et_pb_section][\/et_pb_tab][et_pb_tab title=\u00bbRegistros de propiedad industrial\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb border_width_left=\u00bb1px\u00bb border_color_left=\u00bbrgba(67,165,211,0.32)\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_blurb title=\u00bbMiembros\u00bb use_icon=\u00bbon\u00bb font_icon=\u00bb||fa||900″ icon_color=\u00bb#43a5d3″ icon_placement=\u00bbleft\u00bb _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#235b78″ header_font_size=\u00bb22px\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb||||false|false\u00bb custom_padding=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blurb][et_pb_divider color=\u00bb#43a5d3″ divider_weight=\u00bb2px\u00bb _builder_version=\u00bb4.20.4″ _module_preset=\u00bbdefault\u00bb width=\u00bb70%\u00bb custom_padding=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_divider][dsm_icon_list _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigadora Responsable\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4″ tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blurb title=\u00bbRosa Garc\u00eda Portales\u00bb image=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2024\/02\/DA06-IR-Rosa-G.png\u00bb icon_placement=\u00bbleft\u00bb image_icon_width=\u00bb71px\u00bb _builder_version=\u00bb4.24.1″ _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_color=\u00bb#24a8d7″ body_link_text_color=\u00bb#919191″ custom_padding=\u00bb|||80px|false|false\u00bb border_radii_image=\u00bbon|25%|25%|25%|25%\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Correo electr\u00f3nico:<\/strong> rosam.garcia.portales.sspa@juntadeandalucia.es<\/a> <\/strong>SCOPUS<\/strong><\/a><\/p>\n

[\/et_pb_blurb][dsm_icon_list _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0″][dsm_icon_list_child text=\u00bbCo-Investigadora Responsable\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4″ tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0″]Ser\u00e1 Investigador Asistencial Colaborador el Investigador que no re\u00fane la consideraci\u00f3n de Investigador Posdoctoral. Estar\u00e1n adscritos a un Grupo de Investigaci\u00f3n liderado por un IR. Las funciones ser\u00e1n las que le tenga asignada su IR.[\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blurb title=\u00bbMar\u00eda del Carmen Ord\u00f3\u00f1ez Ca\u00f1izares\u00bb icon_placement=\u00bbleft\u00bb image_icon_width=\u00bb71px\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_color=\u00bb#24a8d7″ body_link_text_color=\u00bb#919191″ custom_padding=\u00bb|||80px|false|false\u00bb hover_enabled=\u00bb0″ border_radii_image=\u00bbon|25%|25%|25%|25%\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0″]<\/p>\n

Correo electr\u00f3nico:<\/strong> maricarmenoc@hotmail.com<\/a>\u00a0<\/strong><\/p>\n

ORCID<\/a><\/p>\n

[\/et_pb_blurb][dsm_icon_list _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigador\/a Asistencial Colaborador\/a\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4″ tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador Asistencial Colaborador el Investigador que no re\u00fane la consideraci\u00f3n de Investigador Posdoctoral. Estar\u00e1n adscritos a un Grupo de Investigaci\u00f3n liderado por un IR. Las funciones ser\u00e1n las que le tenga asignada su IR.[\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20″ include_categories=\u00bb1903″ show_thumbnail=\u00bboff\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb show_pagination=\u00bboff\u00bb _builder_version=\u00bb4.24.0″ _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4″ header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigadores\/as posdoctorales y\/o junior\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4″ tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Esta etapa posdoctoral estar\u00e1 restringida a Investigadores del Instituto que tengan el t\u00edtulo doctor y no contemplados en los perfiles posteriores. Durante su etapa posdoctoral pueden llegar a liderar proyectos de I+D+i como Investigadores Principales, aunque a\u00fan no hayan establecido un nivel significativo de independencia. Adem\u00e1s, pueden tener actividades de docencia y\/o asistencial m\u00e1s all\u00e1 de su trabajo de investigaci\u00f3n. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20″ include_categories=\u00bb1904″ show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb show_pagination=\u00bboff\u00bb disabled_on=\u00bbon|on|on\u00bb _builder_version=\u00bb4.24.0″ _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4″ header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb disabled=\u00bbon\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.24.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbPersonal T\u00e9cnico\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4″ tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.24.0″ _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Esta etapa posdoctoral estar\u00e1 restringida a Investigadores del Instituto que tengan el t\u00edtulo doctor y no contemplados en los perfiles posteriores. Durante su etapa posdoctoral pueden llegar a liderar proyectos de I+D+i como Investigadores Principales, aunque a\u00fan no hayan establecido un nivel significativo de independencia. Adem\u00e1s, pueden tener actividades de docencia y\/o asistencial m\u00e1s all\u00e1 de su trabajo de investigaci\u00f3n. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20″ include_categories=\u00bb1905″ show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb show_pagination=\u00bboff\u00bb _builder_version=\u00bb4.24.0″ _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4″ header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Enfermedades Inflamatorias Inmunomediadas (IMID)Lineas de Investigaci\u00f3n

\n\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t

No Results Found<\/h2>\n\t

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.<\/p>\n<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div> \n\t\t\t\t<\/div>

\n\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t
\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tPautas de tratamiento con upadacitinib, consecuci\u00f3n de los objetivos terap\u00e9uticos y mantenimiento de la respuesta en pacientes con artritis reumatoide de moderada a grave en la pr\u00e1ctica real (Estudio UPHOLD, P20-095)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

ROSA MARIA GARCIA PORTALES – ESTUDIO POSAUTORIZACION COMERCIAL – No aplica – ABBVIE SPAIN S.L.U.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tFactores asociados al descenso de densidad mineral \u00f3sea y a la incidencia de fracturas durante el periodo de descanso terap\u00e9utico con BifosfonatosC\u00f3digo Promotor: Vacaciones Terap\u00e9uticas<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

BLANCA PANERO LAMOTHE – ESTUDIO POSAUTORIZACION INDEPENDIENTE – No aplica – FIBICO. FUNDACION PARA LA INVESTIGACI\u00d3N BIOM\u00c9DICA DE C\u00d3RDOBA<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tEvaluaci\u00f3n de los resultados reportados por el paciente con psoriasis tratado con un f\u00e1rmaco anti IL-17AF a trav\u00e9s de un modelo de atenci\u00f3n farmac\u00e9utica telem\u00e1tica.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

ELENA SANCHEZ YA\u00d1EZ – ESTUDIO OBSERVACIONAL CON MEDICAMENTOS – No aplica – FARMACEUTICOS UNIDADES DE PACIENTES EXTERNOS ILLES BALEARS<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tEstudio observacional para evaluar la adherencia a TREMFYA (Guselkumab) en la pr\u00e1ctica cl\u00ednica en pacientes con psoriasis moderada a grave. ADHERENCE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

ELENA SANCHEZ YA\u00d1EZ – ESTUDIO OBSERVACIONAL CON MEDICAMENTOS – No aplica – BIOCLEVER 2005, S.L.U.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tEstudio observacional ambispectivo para describir la persistencia de la secuenciaci\u00f3n de guselkumab o TNFi como terapia de segunda l\u00ednea para el tratamiento de la artritis psori\u00e1sica activa.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

ROSA MARIA GARCIA PORTALES – ESTUDIO OBSERVACIONAL CON MEDICAMENTOS – No aplica – ADKNOMA HEALTH RESEARCH, S.L.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tEstudio multic\u00e9ntrico, ambispectivo y observacional, en pacientes con psoriasis en placas de moderada a grave, para evaluar su satisfacci\u00f3n con el tratamiento con tildrakizumab.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

ISABEL MOYA CARMONA – ESTUDIO OBSERVACIONAL CON MEDICAMENTOS – No aplica – ALMIRALL S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tEstudio de prevalencia y adecuaci\u00f3n del uso hospitalario de antimicrobianos en Espa\u00f1a.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

ELENA SANCHEZ YA\u00d1EZ – ESTUDIO POSAUTORIZACION INDEPENDIENTE – No aplica – SOCIEDAD ESPA\u00d1OLA DE FARMACIA<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tA multinational, prospective, non-interventional study, to assess real world use of a tocilizumab biosimilar in rheumatoid arthritis patients.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

ROSA MARIA GARCIA PORTALES – ESTUDIO OBSERVACIONAL CON MEDICAMENTOS – No aplica – FRESENIUS KABI SWISSBIOSIM GMBH<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div>

\n\t
<\/div>\n\t
<\/div>\n<\/div><\/div><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t \n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t
\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tClinical characterization and detection of subclinical atherosclerosis in subjects with extreme hyperalphalipoproteinemia – CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Esp\u00edldora-Hern\u00e1ndez, J; D\u00edaz-Antonio, T; Olmedo-Llanes, J; Le\u00f3n, JZ; Rioja, J; Valdivielso, P; S\u00e1nchez-Chaparro, MA; Ariza, MJ – 2024 – 10.1016\/j.arteri.2024.03.005<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tPersonalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs – BIOMEDICINE & PHARMACOTHERAPY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Mu\u00f1oz-Barrera, L; Perez-Sanchez, C; Ortega-Castro, R; Corrales, S; Luque-Tevar, M; Cerd\u00f3, T; Sanchez-Pareja, I; Font, P; Lopez-Mej\u00edas, R; Calvo, J; Abalos-Aguilera, MC; Ruiz-Vilchez, D; Segui, P; Merlo, C; Perez-Venegas, J; Montesino, MDR; Rodriguez-Escalera, C; Barco, CR; Fernandez-Nebro, A; Vazque, NM; Marenco, JL; Monta\u00f1es, JU; Godoy-Navarrete, J; Cabezas-Lucena, AM; Estevez, EC; Aguirre, MA; Gonz\u00e1lez-Gay, MA; Barbarroja, N; Escudero-Contreras, A; Lopez-Pedrera, C – 2024 – 10.1016\/j.biopha.2024.116357<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tReal-world effectiveness and safety of combined calcium 600 mg and cholecalciferol 2000 IU for treating vitamin d deficiency: Results from a nationwide study with focus in osteoporosis – BONE REPORTS<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Pinto-Bonilla, R; Baeza-Noci, J; Blanco, CC; Gumbau, GJV; Fern\u00e1ndez, RJ; Pascual-Pastor, M; Magam\u00f3n, BG; Lamothe, BP; Pastor, CM; Avi\u00f1\u00f3, RI; Aguilar, EG; Saz-Leal, P – 2024 – 10.1016\/j.bonr.2024.101796<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tTelematic Interview in Telepharmacy: a comprehensive guide for pharmacotherapeutic follow-up and and informed drug delivery – FARMACIA HOSPITALARIA<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Barbadillo-Villanueva, S; del Aguila, VA; Robustillo-Cort\u00e9s, MD; Gimeno-Gracia, M; Y\u00e1\u00f1ez, ES; Hermenegildo-Caudevilla, M; Azn\u00e1rez, HN; L\u00f3pez, AL; Vicente, E; Monte-Boquet, E – 2024 – 10.1016\/j.farma.2024.04.008<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tApplication of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project. – REVISTA ESPANOLA DE QUIMIOTERAPIA<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Sanchez-Yanez, Elena; Jose Huertas-Fernandez, Maria; de las Aguas Robustillo-Cortes, Maria; Ramos-Guerrero, Rosa; Fernandez-Espinola, Sergio; Diaz-Acedo, Rocio; Montero-Martin, Violeta; Morillo-Verdugo, Ramon – 2023 – 10.37201\/req\/021.2023<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tHigh incidence of clinical fragility fractures in postmenopausal women with rheumatoid arthritis. A case-control study – BONE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Gomez-Vaquero, Carmen; Hernandez, Jose Luis; Olmos, Jose Manuel; Cerda, Dacia; Calleja, Cristina Hidalgo; Lopez, Juan Antonio Martinez; Arboleya, Luis; Rey, Francisco Javier Aguilar del; Pardo, Silvia Martinez; Vilamajo, Inmaculada Ros; Armangue, Xavier Suris; Grados, Dolors; Audera, Chesus Beltran; Suero-Rosario, Evelyn; Gracia, Inmaculada Gomez; Chamizo, Asuncion Salmoral; Martin-Esteve, Irene; Florez, Helena; Naranjo, Antonio; Castaneda, Santos; Bruno, Soledad Ojeda; Carazo, Sara Garcia; Garcia-Vadillo, Alberto; Vives, Laura Lopez; Martinez-Ferrert, Angels; Panos, Helena Borrell; Acin, Pilar Aguado; Castellanos-Moreira, Raul; Satorra, Pau; Tebe, Cristian; Guanabens, Nuria – 2023 – 10.1016\/j.bone.2022.116654<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tGenetic Polymorphisms of GGH and ABCC2 Are Associated with Methotrexate Intolerance in Patients with Rheumatoid Arthritis<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Escudero-Contreras, A; Lopez-Medina, C; Collantes-Estevez, E; Ortega-Castro, R; Calvo-Gutierrez, J; Mena-Vazquez, N; Panero-Lamothe, B; Manzanares-Martin, B; Caliz-Caliz, R; Jimenez-Morales, A; Ruiz-Jimenez, M; Font-Ugalde, P – 2021<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tIntegrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Luque-Tevar, M; Perez-Sanchez, C; Patino-Trives, AM; Barbarroja, N; de la Rosa, IA; Abalos-Aguilera, MC; Marin-Sanz, JA; Ruiz-Vilchez, D; Ortega-Castro, R; Font, P; Lopez-Medina, C; Romero-Gomez, M; Rodriguez-Escalera, C; Perez-Venegas, J; Ruiz-Montesinos, MD; Dominguez, C; Romero-Barco, C; Fernandez-Nebro, A; Mena-Vazquez, N; Marenco, JL; Uceda-Montanez, J; Toledo-Coello, MD; Aguirre, MA; Escudero-Contreras, A; Collantes-Estevez, E; Lopez-Pedrera, C – 2021<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tPredictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Mena-Vazquez, N; Rojas-Gimenez, M; Romero-Barco, CM; Manrique-Arija, S; Francisco, E; Aguilar-Hurtado, MC; Anon-Onate, I; Perez-Albaladejo, L; Ortega-Castro, R; Godoy-Navarrete, FJ; Urena-Garnica, I; Velloso-Feijoo, ML; Redondo-Rodriguez, R; Jimenez-Nunez, FG; Lamothe, BP; Padin-Martin, MI; Fernandez-Nebro, A – 2021<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tReal-life cost-effectiveness of benralizumab in patients with severe asthma<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Padilla-Galo, A; Garcia-Ruiz, AJ; Abitbol, RCL; Olveira, C; Rivas-Ruiz, F; Soler, NGA; Morales, MP; Azcona, BV; Tortajada-Goitia, B; Moya-Carmona, I; Levy-Naon, A – 2021<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tForced normalization: case series from a Spanish epilepsy unit<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Barrios, LC; Martin, GG; Godoy, JR; Acebal, MR; Munoz, MIC – 2020<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tNeurosarcoidosis: Analysis of a series of 20 patients<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Barrios, LC; Costalago, MA; Conde, AH; de los Rios, RAD; Portales, RG; Martin, GG – 2020<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tReal-life experience with benralizumab during 6 months<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Padilla-Galo, A; Levy-Abitbol, R; Olveira, C; Azcona, BV; Morales, MP; Rivas-Ruiz, F; Tortajada-Goitia, B; Moya-Carmona, I; Levy-Naon, A – 2020<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tSubclinical Arteriosclerosis is Associated with Common Vascular Risk Factors in Long-Term Survivors of Testicular Cancer<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Espildora-Hernandez, J; Diaz-Antonio, T; Baena-Espinar, J; Alonso-Calderon, I; Rioja, J; Alba-Conejo, E; Valdivielso, P; Sanchez-Chaparro, MA – 2020<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tComparison of long-term clinical evolution in highly myopic eyes with vertical oval-shaped dome with or without untreated serous retinal detachment<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Garcia-Ben, A; Garcia-Basterra, I; Gonzalez-Gomez, A; Baquero-Aranda, I; Morillo-Sanchez, MJ; Soler-Garcia, A; Garcia-Campos, JM – 2019<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tLongitudinal study of visual function in patients with relapsing-remitting multiple sclerosis with and without a history of optic neuritis<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Gomez, AG; Garcia-Ben, A; Garcia, AS; Garcia-Basterra, I; Parrado, FP; Garcia-Campos, JM – 2019<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tEvaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Ferreiro-Iglesias, A; Montes, A; Perez-Pampin, E; Canete, JD; Raya, E; Magro-Checa, C; Vasilopoulos, Y; Caliz, R; Ferrer, MA; Joven, B; Carreira, P; Balsa, A; Pascual-Salcedo, D; Blanco, FJ; Moreno-Ramos, MJ; Manrique-Arija, S; Ordonez, MD; Alegre-Sancho, JJ; Narvaez, J; Navarro-Sarabia, F; Moreira, V; Valor, L; Garcia-Portales, R; Marquez, A; Gomez-Reino, JJ; Martin, J; Gonzalez, A – 2019<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t

\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tFACTORS ASSOCIATED WITH SEROUS RETINAL DETACHMENT IN HIGHLY MYOPIC EYES WITH VERTICAL OVAL-SHAPED DOME<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t

Garcia-Ben, A; Sanchez, MJM; Gomez, AG; Garcia-Basterra, I; Garcia, AS; Garcia-Campos, JM – 2019<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div>

\n\t
<\/div>\n\t
<\/div>\n<\/div><\/div><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t \n\t\t\t\t<\/div>
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t

No Results Found<\/h2>\n\t

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.<\/p>\n<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div> \n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t
    <\/ul>\n\t\t\t\t<\/div>\n\t\t\t<\/div>
  • \n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
    <\/span>Investigadora Responsable<\/span><\/div>\n\t\t\t<\/li>Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[],"project_tag":[],"class_list":["post-11397","project","type-project","status-publish","hentry"],"acf":[],"yoast_head":"\nDA-06 - Ibima<\/title>\n<meta name=\"description\" content=\"El grupo de investigaci\u00f3n asociado DA-06 se dedica a investigar enfermedades inflamatorias inmunomediadas\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/project\/da-06\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DA-06 - Ibima\" \/>\n<meta property=\"og:description\" content=\"El grupo de investigaci\u00f3n asociado DA-06 se dedica a investigar enfermedades inflamatorias inmunomediadas\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/project\/da-06\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-15T15:46:23+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/project\\\/da-06\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/project\\\/da-06\\\/\",\"name\":\"DA-06 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2023-09-15T09:47:59+00:00\",\"dateModified\":\"2025-12-15T15:46:23+00:00\",\"description\":\"El grupo de investigaci\u00f3n asociado DA-06 se dedica a investigar enfermedades inflamatorias inmunomediadas\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/project\\\/da-06\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/es\\\/project\\\/da-06\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/project\\\/da-06\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Proyectos\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/project\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"DA-06\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DA-06 - Ibima","description":"El grupo de investigaci\u00f3n asociado DA-06 se dedica a investigar enfermedades inflamatorias inmunomediadas","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/project\/da-06\/","og_locale":"en_GB","og_type":"article","og_title":"DA-06 - Ibima","og_description":"El grupo de investigaci\u00f3n asociado DA-06 se dedica a investigar enfermedades inflamatorias inmunomediadas","og_url":"https:\/\/ibima.eu\/en\/project\/da-06\/","og_site_name":"Ibima","article_modified_time":"2025-12-15T15:46:23+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/es\/project\/da-06\/","url":"https:\/\/ibima.eu\/es\/project\/da-06\/","name":"DA-06 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2023-09-15T09:47:59+00:00","dateModified":"2025-12-15T15:46:23+00:00","description":"El grupo de investigaci\u00f3n asociado DA-06 se dedica a investigar enfermedades inflamatorias inmunomediadas","breadcrumb":{"@id":"https:\/\/ibima.eu\/es\/project\/da-06\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/es\/project\/da-06\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/es\/project\/da-06\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Proyectos","item":"https:\/\/ibima.eu\/es\/project\/"},{"@type":"ListItem","position":3,"name":"DA-06"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/11397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=11397"}],"version-history":[{"count":4,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/11397\/revisions"}],"predecessor-version":[{"id":58943,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/11397\/revisions\/58943"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=11397"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project_category?post=11397"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project_tag?post=11397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}